Clinical trialNCT02453282Active, not recruitingPhase 3Interventional

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

SponsorAstraZenecaEnrollment1,118Non-Small-Cell Lung Carcinoma NSCLC

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced or metastatic NSCLC

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Naiyer Rizvi, MD
Columbia University Medical Center, New York, NY, USA
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Stuart McIntosh, MD
AstraZeneca, Alderley Park, Cheshire, UK
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

196 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Research Site
Box Hill, Australia
Research Site
Gosford, Australia
Research Site
Kogarah, Australia
Research Site
Melbourne, Australia
Research Site
Port Macquarie, Australia
Research Site
Southport, Australia
Research Site
St Leonards, Australia

Belgium

Research Site
Brussels, Belgium
Research Site
Charleroi, Belgium
Research Site
Duffel, Belgium
Research Site
Leuven, Belgium
Research Site
Liège, Belgium

Canada

Research Site
Greater Sudbury, Ontario, Canada
Research Site
Kingston, Ontario, Canada
Research Site
Newmarket, Ontario, Canada
Research Site
Oshawa, Ontario, Canada
Research Site
Saint Catherines, Ontario, Canada
Research Site
Sault Ste. Marie, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Regina, Saskatchewan, Canada
Research Site
Saskatoon, Saskatchewan, Canada

France

Research Site
Bordeaux, France
Research Site
Brest, France
Research Site
Créteil, France
Research Site
Lille, France
Research Site
Lyon, France
Research Site
Marseille, France

Germany

Research Site
Aachen, Germany
Research Site
Bad Berka, Germany
Research Site
Berlin, Germany
Research Site
Berlin, Germany
Research Site
Freiburg im Breisgau, Germany
Research Site
Gauting, Germany
Research Site
Hamburg, Germany
Research Site
Heidelberg, Germany
Research Site
Hemer, Germany
Research Site
Homburg/Saar, Germany
Research Site
Immenhausen, Germany
Research Site
Löwenstein, Germany
Research Site
Lübeck, Germany

156 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Gemcitabine + CarboplatinGemcitabine + CisplatinMEDI4736MEDI4736+TremelimumabPaclitaxel + CarboplatinPemetrexed + CarboplatinPemetrexed + CisplatinTremelimumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 21 Jul 2015
Primary completion: 4 Oct 2018
Completion: 31 Dec 2026
Last update posted: 6 Aug 2026
Registered enrollment: 1,118
Registry id: NCT02453282

Cross-registrations

EU-CTR / CTIS (EudraCT)2015-001279-39

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.